Education
About Us
Working with TipRanks
Follow Us
Abivax SA Sponsored ADR (ABVX)
NASDAQ:ABVX
ABVX Stock Chart & Stats
$120.34
-$0.09(-1.29%)
At close: 4:00 PM EST
$120.34
-$0.09(-1.29%)
Day’s Range― - ―
52-Week Range$4.77 - $148.83
Previous CloseN/A
Volume62.24K
Average Volume (3M)888.78K
Market Cap
$10.04B
Enterprise Value$8.70B
Total Cash (Recent Filing)$60.95M
Total Debt (Recent Filing)$84.57M
Price to Earnings (P/E)―
Beta2.51
Next Earnings
Mar 23, 2026EPS Estimate
-1.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding79,167,435
10 Day Avg. Volume1,044,324
30 Day Avg. Volume888,781
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)10.98
Price to Sales (P/S)41.30
P/FCF Ratio-2.88
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue923.82
Enterprise Value/Gross Profit923.82
Enterprise Value/Ebitda-38.56
Forecast
1Y Price Target
$148.86Price Target Upside23.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-3.51
Revenue Forecast (FY)$4.84M
Bulls Say, Bears Say
Bulls Say
Clinical MilestonesPhase 3 maintenance results and additional induction readouts could determine regulatory submission prospects and materially influence perceptions of the drug's clinical efficacy.
Commercial PotentialPhysician survey responses, broad activity across treatment lines, and potential anti‑fibrotic effects relevant to Crohn's disease suggest meaningful uptake and revenue upside beyond the ulcerative colitis market.
Safety ProfileA data safety monitoring board report finding no new safety concerns combined with a generally benign tolerability profile supports prescriber confidence compared with other oral therapies.
Bears Say
Commercial And Launch ExecutionLack of a chief commercial officer, no established commercial sales infrastructure, and absence of an experienced US manufacturer raise regulatory and launch execution risk if approval is achieved.
Financing RiskLimited cash runway and high cash burn increase the probability of additional financing that could dilute shareholders and affect development timelines.
Valuation And M&A SpeculationReliance on acquisition speculation rather than core clinical data has driven stock volatility and could produce sharp downside if deal expectations are not met or pivotal data fall short.
Abivax SA Sponsored ADR News
ABVX FAQ
What was Abivax SA Sponsored ADR’s price range in the past 12 months?
Abivax SA Sponsored ADR lowest stock price was $4.77 and its highest was $148.83 in the past 12 months.
What is Abivax SA Sponsored ADR’s market cap?
Abivax SA Sponsored ADR’s market cap is $10.04B.
When is Abivax SA Sponsored ADR’s upcoming earnings report date?
Abivax SA Sponsored ADR’s upcoming earnings report date is Mar 23, 2026 which is today.
How were Abivax SA Sponsored ADR’s earnings last quarter?
Currently, no data Available
Is Abivax SA Sponsored ADR overvalued?
According to Wall Street analysts Abivax SA Sponsored ADR’s price is currently Undervalued.
Does Abivax SA Sponsored ADR pay dividends?
Abivax SA Sponsored ADR does not currently pay dividends.
What is Abivax SA Sponsored ADR’s EPS estimate?
Abivax SA Sponsored ADR’s EPS estimate is -1.35.
How many shares outstanding does Abivax SA Sponsored ADR have?
Abivax SA Sponsored ADR has 79,167,435 shares outstanding.
What happened to Abivax SA Sponsored ADR’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Abivax SA Sponsored ADR?
Currently, no hedge funds are holding shares in ABVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abivax SA Sponsored ADR Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$148.86 (23.70% Upside)
$148.86 (23.70% Upside)
Blogger Sentiment
Bullish
ABVX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 2.2%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Company Description
Abivax SA Sponsored ADR
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
ABVX Stock 12 Month Forecast
Average Price Target
$148.86
▲(23.70% Upside)
Technical Analysis
Cytokinetics
―
Rhythm Pharmaceuticals
―
Legend Biotech
―
Atrium Therapeutics, Inc.
―
Nuvalent
―
Ownership Overview
―
Insiders
5.34% Mutual Funds
42.38% Other Institutional Investors
48.60% Public Companies and Individual Investors